November 13, 2008 - Basilea Pharmaceutica Ltd. announces that ceftobiprole (Zevtera), the anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Swissmedic for the treatment of complicated skin and soft tissue infections including diabetic foot infections.
the details can be read here.
No comments:
Post a Comment